Adagene/$ADAG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Adagene
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
Ticker
$ADAG
Sector
Primary listing
Employees
128
Headquarters
Website
Adagene Metrics
BasicAdvanced
$233m
-
-$0.38
0.60
-
Price and volume
Market cap
$233m
Beta
0.6
52-week high
$4.75
52-week low
$1.30
Average daily volume
145k
Financial strength
Current ratio
3.074
Quick ratio
3.014
Long term debt to equity
2.296
Total debt to equity
12.068
Interest coverage (TTM)
-46.29%
Profitability
EBITDA (TTM)
-20.999
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-229.56%
Operating margin (TTM)
-279.48%
Effective tax rate (TTM)
1.66%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-16.00%
Return on equity (TTM)
-34.39%
Valuation
Price to revenue (TTM)
21.723
Price to book
4.73
Price to tangible book (TTM)
4.73
Price to free cash flow (TTM)
-10.631
Free cash flow yield (TTM)
-9.41%
Free cash flow per share (TTM)
-0.332
Growth
Revenue change (TTM)
7,332.76%
Earnings per share change (TTM)
-49.48%
3-year revenue growth (CAGR)
-6.19%
3-year earnings per share growth (CAGR)
-41.26%
What the Analysts think about Adagene
Analyst ratings (Buy, Hold, Sell) for Adagene stock.
Adagene Financial Performance
Revenues and expenses
Adagene Earnings Performance
Company profitability
Adagene News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs